

Applicants: Munn et al.

Serial No. 10/780,797

Confirmation No. 1508

Filed: February 17, 2004

Title: USE OF INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE IN COMBINATION WITH OTHER THERAPEUTIC MODALITIES

Amendments to the Specification

Please replace the paragraph beginning at page 11, line 29, with the following amended paragraph.

Figures ~~11A-11E~~ 11A-11D. Administration of 1-MT enhances immune-mediated host anti-tumor effect when administered with radiation or cyclophosphamide. Mice were injected subcutaneously (SQ) with 4×10^4 B16F10 cells. In Fig. 11A 1MT (20 mg/day of a DL racemic mixture) was administered SQ by continuous-release copolymer pellets, with or without 500 cGy of total-body γ -irradiation. Control mice received vehicle pellets without drug. In Fig. 11B 1MT was administered with cyclophosphamide (CPM) (150 mg/kg, one dose). Fig. 11C represents 1MT and cyclophosphamide in rag1-knockout hosts. Fig. 11D represents the more potent pure D-isomer of 1MT, given 5 mg/day, with cyclophosphamide.